GSK-626616

• CAT Number: I007119
• CAS Number: 1025821-33-3
• Molecular Formula: C18H10Cl2N4OS
• Molecular Weight: 401.265
• Purity: 98%
• Target: YAK3/DYRK3 kinase inhibitor
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term or -20 °C for long term
• IUPAC Name: (5Z)-2-(2,6-dichloroanilino)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazol-4-one
• InChI: InChI=1S/C18H10Cl2N4OS/c19-11-2-1-3-12(20)16(11)23-18-24-17(25)15(26-18)9-10-4-5-13-14(8-10)22-7-6-21-13/h1-9H,(H,23,24,25)/b15-9-
• InChIKey: RJPNRXFBYZVRIB-DHDCSXOGSA-N
• SMILES: C1=CC(=C(C(=C1)Cl)NC2=NC(=O)C(=CC3=CC4=NC=CN=C4C=C3)S2)Cl

GSK 626616 (CAT: I007119) is a selective inhibitor of the YAK3 (also known as DYRK3) kinase. YAK3 is a protein kinase that plays a role in various cellular processes, including cell proliferation and differentiation. By inhibiting YAK3, GSK 626616 has the potential to modulate these cellular processes and may have therapeutic applications in certain conditions. Specifically, GSK 626616 has been investigated as a chemoprotective agent for the treatment of chemotherapy-induced anemia, which is a common side effect of cancer treatment. Further research is being conducted to explore its efficacy and safety in this context.

Overview of Clinical Research

GSK-626616 is a DYRK kinase inhibitor. The phase-I clinical trials was initiated in Chemotherapy-induced anaemia/Chemoprotection in Australia (PO) in 2006.

Reference

1: Wippich F, Bodenmiller B, Trajkovska MG, Wanka S, Aebersold R, Pelkmans L. Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling. Cell. 2013 Feb 14;152(4):791-805. doi: 10.1016/j.cell.2013.01.033. PubMe